MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/490/0.01/21.03.25 | Real-time Bid/Ask 09:16:03 2024-07-04 EDT | ||
| 0.43 EUR / 0.45 EUR | +4.76% |
|
| Current month | -8.70% | ||
| 1 month | -6.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 0.42 | 0.00% |
| 24-07-03 | 0.42 | -8.70% |
| 24-07-02 | 0.46 | +2.22% |
| 24-07-01 | 0.45 | -2.17% |
| 24-06-28 | 0.46 | -2.13% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 06:48 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG29XC |
| ISIN | DE000MG29XC4 |
| Date issued | 2024-04-12 |
| Strike | 490 $ |
| Maturity | 2025-03-21 (260 Days) |
| Parity | 100 : 1 |
| Emission price | 0.22 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.56 € |
|---|---|
| Lowest since issue | 0.19 € |
| Spread | 0.02 € |
| Spread % | 4.44% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
